Vázquez LY, Bravo OJC, Hernández GC, Ruíz QNC, Soriano BCA

Language: Spanish
References: 35
Page: 277-282
PDF size: 104.73 Kb.

ABSTRACT

Background. Retinopathy of prematurity (ROP) is defined as a peripheral proliferative vitreoretinopathy in which immaturity (determined by gestational age and birth weight) and oxygen are more decisive factors. We undertook this study to analyze the relative risk for development of ROP in relation to gestational age and birth weight in infants.
Methods. We carried out a retrospective, analytical, cross-sectional, single center trial in preterm infants with a gestational age ‹37 weeks and a birth weight ‹2,000 g. We performed fundus examination with binocular indirect ophthalmoscopy at different times according to gestational age. Injuries are accounted for using the international classification.
Results. We included two groups: I) healthy individuals and II) those with retinopathy of prematurity. Group I included 217 healthy subjects, 91 females and 126 males, with a mean gestational age of 30.95 ± 2.7 weeks and a weight of 1291.98 ± 255.93 g (range: 620-2035). Group II was comprised of 127 patients, 65 females and 62 males with a mean gestational age of 29.37 ± 1.77 weeks (range: 26-34) and a weight of 1089.31 ± 194.74 g (range: 630-1650). Stage 1 retinopathy predominated (70.1%), followed by stage 2 (21.3%) and stage 3 (7.1%); 9.4% presented a type 1 prethreshold retinopathy and 4.7% threshold. The group of 28-29 weeks showed a factor of 2.37 times more risk of developing ROP and was the group with the highest incidence with 64.13% at 30-31 weeks after which the risk begins to decrease.
Conclusions. Preterm infants with gestational age between 28 and 29 weeks are at increased risk for developing ROP.

REFERENCES

1. Terry T. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am J Ophthalmol 1942;25:203-204.

2. Campbell K. Intensive oxygen therapy as a possible cause for retrolental fibroplasia. A clinical approach. Med J Aust 1951;2:48-50.

3. Heath P. Pathology of the retinopathy of prematurity: retrolental fibroplasia. Am J Ophthalmol 1951;34:1249-1259.

4. Kinsey VE, Hemphill FM. Etiology of retrolental fibroplasia and preliminary report of cooperative study of retrolental fibroplasia. Trans Am Acad Ophthalmol Otolaryngol 1955;59:15-24.

5. Gibson DL, Sheps SB, Uh SH, Schechter MT, McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics 1990;86:405-412.

6. Gilbert C, Fielder F, Gordillo L, Quinn G, Semiglia R, Visintin P, et al; for the International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115:e518-e525.

7. Gilbert CE, Foster A. Childhood blindness in the context of VISION 2020—the right to sight. Bull WHO 2001;79:227-232.

8. Gilbert C, Rahi J, Eckstein M, O´Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet 1997;350:12-14.

9. Zimmermann CJ, Fortes FJB, Tartarella MB, Zin A, Dorneles JI Jr. Prevalence of retinopathy of prematurity in Latin America. Clin Ophthalmol 2011:5 1687-1695.

10. Zepeda RLC, Gutiérrez PJA, De la Fuente TMA, Angulo CE, Ramos PE, Quinn GE. Detection and treatment for retinopathy of prematurity in Mexico: need for effective programs. J AAPOS 2008;12:225-226.

11. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS 1999;3:26-32.

12. Mathew MR, Fern AI, Hill R. Retinopathy of prematurity: are we screening too many babies? Eye (Lond) 2002;16:538-542.

13. Holmström G, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity —a population-based study. Acta Ophthalmol Scand 1998;76:204-207.

14. Olea JL, Corretger FJ, Salvat M, Frau E, Galiana C, Fiol M. Factores de riesgo en la retinopatía del prematuro. An Esp Pediatr 1997;47:172-176.

15. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicentre trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988;106:471-479.

16. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.

17. Lim J, Fong DS, Dang Y. Decreased prevalence of retinopathy of prematurity in an inner-city hospital. Ophtalmic Sur Lasers 1999;30:12-16.

18. Termote J, Schalij-Delfos NE, Brouwers HAA, Donders ART, Cats BP. New developments in neonatology: less severe retinopathy of prematurity? J Pediatr Ophthalmol Strabismus 2000;37:142-148.

19. Ng YK, Fielder AR, Shaw DE, Levene MI. Epidemiology of retinopathy of prematurity. Lancet 1988;2:1235-1238.

20. Hameed B, Shyamanur K, Kotecha S, Manktelow B, Woodruff G, Draper ES, et al. Trends in the incidence of severe retinopathy of prematurity in a geographically defined population over a 10-year period. Pediatrics 2004;113:1653-1657.

21. Bossi E, Koerner F. Retinopathy of prematurity. Intensive Care Med 1995;21:241-246.

22. Pallás CR, Tejada P, Medina MC, Martín MJ, Orbea C, Barrios MC. Retinopatía del prematuro: nuestra experiencia. An Esp Pediatr 1995;42:52-56.

23. Blair BM, O'Halloran HS, Pauly TH, Stevens JL. Decreased incidence of retinopathy of prematurity, 1995-1997. JAAPOS 2001;5:118-122.

24. Holmström G, El Azazi M, Jacobson L, Lennerstrand G. A population-based, prospective study of the development of ROP in prematurely born children in the Stockholm area of Sweden. Br J Ophthalmol 1993;77:417-423.

25. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628-1640.

26. Párraga QMJ, Sánchez PR, Barreiro LJC, Cañete ER, Fernández GF, Zapatero MM, et al. Retinopatía del prematuro. Resultados tras un año de seguimiento. An Esp Pediatr 1996;44:482-484.

27. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quitos M, et al; for the Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116:15-23.

28. American Academy of Pediatrics, Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-576.

29. Secretaría de Salud. Manejo de la retinopatía del recién nacido prematuro. Lineamiento técnico. Disponible en: http://saludmaternamedicos.blogspot.mx/2011/09/lineamientotecnico-manejo-de-la.html#!/2011/09/lineamiento-tecnicomanejo-de-la.html

30. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004;14(suppl A):S140-S144.

31. Msall ME, Phelps DL, Hardy RJ, Dobson V, Quinn GE, Summers CG, et al. Educational and social competencies at 8 years in children with threshold retinopathy of prematurity in the CRYO-ROP multicenter study. Pediatrics 2004;113:790-799.

32. Holmström G, El Azazi M, Kugelberg U. Ophthalmological long term follow up of preterm infants: a population based, prospective study of the refraction and its development. Br J Ophthalmol 1998;82:1265-1271.

33. Ricci B. Refractive errors and ocular motility disorders in preterm babies with and without retinopathy of prematurity. Ophthalmologica 1999;213:295-299.

34. Good WV. Early treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol 2006;90:1378-1382.

35. Larsson EK, Holmström GE. Development of astigmatism and anisometropia in preterm children during the first 10 years of life: a population based study. Arch Ophthalmol 2006;124:1608-1614.